Platin desensitizations in thoracic malignancies and risk factors for breakthrough reactions
Although platin desensitization is a safe and effective alternative for patients with hypersensitivity reactions (HSRs), sometimes breakthrough reactions (BTRs) can be encountered. However, data about the risk factors for BTRs are limited. The aim of this study is to define the outcomes of desensitization, the characteristics of BTRs, and to identify the risk factors for BTRs with platins in thoracic malignancies. This is a retrospective report of patients with thoracic malignancies who underwent platin desensitization. Patients' demographics, initial HSR characteristics, skin test results, desensitization outcomes, and BTR characteristics were recorded. Thirty-three lung cancer and 14 malignant pleural mesothelioma (MPM) patients were included in the study. The culprit drug was cisplatin in 29 and was carboplatin in 18 patients. Skin test positivity was 43.5% with cisplatin, 50% with carboplatin, and it was found to be higher if the interval between the initial HSR and skin testing (ST) was ˃20 days (p = 0.027). One hundred and five desensitization courses were performed. Twenty-two patients had 33 BTRs. Skin test positivity was higher in the BTR-positive group (p = 0.025). BTRs (18.2%; n = 6) were more severe than initial HSR. In the case of epinephrine administration during initial HSR, epinephrine administration during the first BTR was found to be more (p = 0.036). The target dose was achieved in 92.4% of desensitization courses. The number of previous platin infusions ≥10 was found to be an independent risk factor for BTR development (p = 0.036 OR:17.641, 95% CI: 1.211-256.971). Identification of risk factors for BTR will guide appropriate management and desensitization approaches for platin HSRs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:51 |
|---|---|
| Enthalten in: |
Allergologia et immunopathologia - 51(2023), 2 vom: 08., Seite 130-136 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Buhari, Gözde Köycü [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastic Agents |
|---|
| Anmerkungen: |
Date Completed 15.03.2023 Date Revised 15.03.2023 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.15586/aei.v51i2.779 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354216821 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354216821 | ||
| 003 | DE-627 | ||
| 005 | 20231226061735.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.15586/aei.v51i2.779 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1180.xml |
| 035 | |a (DE-627)NLM354216821 | ||
| 035 | |a (NLM)36916098 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Buhari, Gözde Köycü |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Platin desensitizations in thoracic malignancies and risk factors for breakthrough reactions |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.03.2023 | ||
| 500 | |a Date Revised 15.03.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Although platin desensitization is a safe and effective alternative for patients with hypersensitivity reactions (HSRs), sometimes breakthrough reactions (BTRs) can be encountered. However, data about the risk factors for BTRs are limited. The aim of this study is to define the outcomes of desensitization, the characteristics of BTRs, and to identify the risk factors for BTRs with platins in thoracic malignancies. This is a retrospective report of patients with thoracic malignancies who underwent platin desensitization. Patients' demographics, initial HSR characteristics, skin test results, desensitization outcomes, and BTR characteristics were recorded. Thirty-three lung cancer and 14 malignant pleural mesothelioma (MPM) patients were included in the study. The culprit drug was cisplatin in 29 and was carboplatin in 18 patients. Skin test positivity was 43.5% with cisplatin, 50% with carboplatin, and it was found to be higher if the interval between the initial HSR and skin testing (ST) was ˃20 days (p = 0.027). One hundred and five desensitization courses were performed. Twenty-two patients had 33 BTRs. Skin test positivity was higher in the BTR-positive group (p = 0.025). BTRs (18.2%; n = 6) were more severe than initial HSR. In the case of epinephrine administration during initial HSR, epinephrine administration during the first BTR was found to be more (p = 0.036). The target dose was achieved in 92.4% of desensitization courses. The number of previous platin infusions ≥10 was found to be an independent risk factor for BTR development (p = 0.036 OR:17.641, 95% CI: 1.211-256.971). Identification of risk factors for BTR will guide appropriate management and desensitization approaches for platin HSRs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a breakthrough reaction | |
| 650 | 4 | |a chemotherapy | |
| 650 | 4 | |a desensitization | |
| 650 | 4 | |a hypersensitivity reaction | |
| 650 | 4 | |a platin | |
| 650 | 7 | |a Carboplatin |2 NLM | |
| 650 | 7 | |a BG3F62OND5 |2 NLM | |
| 650 | 7 | |a Cisplatin |2 NLM | |
| 650 | 7 | |a Q20Q21Q62J |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Epinephrine |2 NLM | |
| 650 | 7 | |a YKH834O4BH |2 NLM | |
| 700 | 1 | |a Kalkan, İlkay Koca |e verfasserin |4 aut | |
| 700 | 1 | |a Ateş, Hale |e verfasserin |4 aut | |
| 700 | 1 | |a Bahçecioğlu, Sakine Nazik |e verfasserin |4 aut | |
| 700 | 1 | |a Demir, Şenay |e verfasserin |4 aut | |
| 700 | 1 | |a Yeşilkaya, Selma |e verfasserin |4 aut | |
| 700 | 1 | |a Solak, Gürgün Tuğçe Vural |e verfasserin |4 aut | |
| 700 | 1 | |a Aksu, Kurtuluş |e verfasserin |4 aut | |
| 700 | 1 | |a Erkekol, Ferda Öner |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Allergologia et immunopathologia |d 1973 |g 51(2023), 2 vom: 08., Seite 130-136 |w (DE-627)NLM000045926 |x 1578-1267 |7 nnns |
| 773 | 1 | 8 | |g volume:51 |g year:2023 |g number:2 |g day:08 |g pages:130-136 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.15586/aei.v51i2.779 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 51 |j 2023 |e 2 |b 08 |h 130-136 | ||